A mutant form of p135tyk2, an interferon-α inducible tyrosine kinase, suppresses the transformed phenotype of Daudi cells

Leukemia

Volumn 10, Issue 3, 1996, Pages 543-551

  Davis, E ^a   Krishnan, K ^a   Yan, H ^a   Newcomb, E W ^b   Krolewski, J J ^a  

^a The New York Presbyterian Hospital   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Interferon ; Intracellular signaling; Tumor suppressor; tyk2; Tyrosine kinase

Indexed keywords

ALPHA INTERFERON; MUTANT PROTEIN; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOGENICITY; CELL TRANSFORMATION; COLONY FORMING UNIT; CONTROLLED STUDY; DAUDI CELL; DNA TRANSFECTION; ENZYME ACTIVITY; ENZYME INDUCTION; GROWTH REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0029670224     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Ann Rev Biochem 1987; 56: 727-777.
2. Sen GC, Lengyel P. The interferon system: a bird's eye view of its biochemistry. J Biol Chem 1992; 267: 5017-5020.
3. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
4. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon α/β signaling pathway. Cell 1992; 70: 313-322.
5. Muller M et al. The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction. Nature 1993; 366: 129-135.
6. Wilks AF. Two putative protein tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci USA 1989; 86: 1603-1607.
7. Firmbach-Kraft I et al. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 1990; 5: 1329-1336.
8. Wilks AF et al. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991; 11: 2057-2065.
9. Harpur AG et al. JAK-2, a third member of the JAK family of protein tyrosine kinases. Oncogene 1992; 7: 1347-1353.
10. Silvennoinen O et al. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc Natl Acad Sci USA 1993; 90: 8429-8433.
11. Cance WG, Craven RJ, Weiner TM, Liu ET. Novel protein kinases expressed in human breast cancer. Int J Cancer 1993; 54: 571-577.
12. Binari R, Perrimon N. Stripe-specific regulation of pair-rule genes by hopscotch, a putative Jak family tyrosine kinase in Drosophila. Genes Dev 1994; 8: 300-312.
13. Witthuhn BA et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 1994; 370: 153-157.
14. Kawamura M et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci USA 1994; 91: 6374-6378.
15. Takakashi T, Shirasawa T. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases. FEBS Lett 1994; 342: 124-128.
16. Bernards A. Predicted tyk2 protein contains two tandem protein kinase domains. Oncogene 1991; 6: 1185-1187.
17. Hanks SK. Eukaryotic protein kinases. Curr Opin Struct Biol 1991; 1: 369-383.
18. tyk2, an interferon-α-activated tyrosine kinase, is physically associated with an interferon-α receptor. J Biol Chem 1994; 269: 3518-3522.
19. tyk2 tyrosine kinase. Mol Cell Biol 1994; 14: 8133-8142.
20. Platanias LC, Colamonici OR. Interferon α induces rapid tyrosine phosphorylation of the α subunit of its receptor. J Biol Chem 1992; 267: 24053-24057.
21. Novick D, Cohen B, Rubinstein M. The human interferon α/β receptor: characterization and molecular cloning. Cell 1994; 77: 391-400.
22. Kumar R, Atlas I. Interferon α induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: role in growth regulation. Proc Natl Acad Sci USA 1992; 89: 6599-6603.
23. Zhang K, Kumar R. Interferon-α inhibits cyclin E- and cyclin D1-dependent cdk-2 kinase activity associated with Rb protein and E2F in Daudi cells. Biochem Biophys Res Comm 1994; 200: 522-528.
24. Lengyel P. Tumor-suppressor genes: news about the interferon connection. Proc Natl Acad Sci USA 1993; 90: 5893-5895.
25. Koromilas AE et al. Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 1992; 257: 1685-1689.
26. Meurs EF et al. Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1993; 90: 232-236.
27. Barber GN et al. The 58 kilodalton inhibitor of the interferon-induced double-stranded RNA-activated protein kinase is a tetratricopeptide repeat protein with oncogenic properties. Proc Natl Acad Sci USA 1994; 91: 4278-4282.
28. Harada H et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of the IFN and IFN-inducible genes. Cell 1989; 58: 729-739.
29. Pine R et al. Purification and cloning of interferon-stimulated gene factor 2 (ISGF2): 1SGF2 (IRF-1) can bind to the promoters of both beta interferon- and interferon-stimulated genes but is not a primary transcriptional activator of either. Mol Cell Biol 1990; 10: 2448-2457.
30. Tanaka N et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994; 77: 829-839.
31. Sugden B, Marsh K, Yates J. A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol Cell Biol 1985; 5: 410-413.
32. Groger RK, Morrow DM, Tykocinski ML. Directional anti-sense and sense cDNA cloning using Epstein-Barr virus episomal expression vectors. Gene 1989; 81: 285-294.
33. Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogony of the catalytic sites. Science 1988; 241: 42-52.
34. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: a Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1989.
35. Kolodziej PA, Young RA. Epitope tagging and protein surveillance. Methods Enzymol 1991; 194: 508-519.
36. Pear WS, Nolan G, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392-8396.
37. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294-5299.
38. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
39. c-src. Nature 1991; 351: 69-72.
40. Cooper JA, Howell B. The when and how of Src regulation. Cell 1993; 73: 1051-1054.
41. lck by the leukocyte common antigen (CD45). Oncogene 1990; 5: 809-813.
42. Greenlund AC, Farrar MA, Viviano BL, Schreiber RD. Ligand-induced IFNγ receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J 1994; 13: 1591-1600.
43. Sawyers CL et al. The nuclear tyrosine kinase c-abl negatively regulates cell growth. Cell 1994; 77: 121-131.
44. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome positive leukemias. New Engl J Med 1988, 319: 990-998.
45. Muller U et al. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264: 1918-1921.
46. Li J, Petryshyn RA. Activation of the double-stranded RNA-dependent eIF-2a kinase by cellular RNA from 3T3-F442A cells. Eur J Biochem 1991; 195: 41-48.
47. Willman CL et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993; 259: 968-971.
48. Kantarjian HM et al. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691-703.
49. Ozer H et al Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: cancer and leukemia group B study 8583. Blood 1993; 82: 2975-2984.
50. Solal-Celigny P et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. New Engl J Med 1993; 329: 1608-1614.